Versant Capital Management Inc Purchases 169 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Versant Capital Management Inc boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 105.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 330 shares of the pharmaceutical company’s stock after acquiring an additional 169 shares during the period. Versant Capital Management Inc’s holdings in Vertex Pharmaceuticals were worth $133,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mutual Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 0.6% during the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock worth $1,751,000 after buying an additional 21 shares during the period. Daymark Wealth Partners LLC grew its holdings in Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 22 shares during the period. Grove Bank & Trust raised its position in shares of Vertex Pharmaceuticals by 5.7% during the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock valued at $191,000 after acquiring an additional 22 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC lifted its stake in shares of Vertex Pharmaceuticals by 3.3% in the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 747 shares of the pharmaceutical company’s stock valued at $350,000 after purchasing an additional 24 shares during the period. Finally, Foundations Investment Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 3.2% in the 2nd quarter. Foundations Investment Advisors LLC now owns 763 shares of the pharmaceutical company’s stock worth $358,000 after purchasing an additional 24 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $407.11 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a market capitalization of $104.84 billion, a price-to-earnings ratio of -204.58 and a beta of 0.36. The stock’s 50 day moving average price is $456.78 and its two-hundred day moving average price is $470.61. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the firm posted $3.67 EPS. The company’s quarterly revenue was up 11.6% on a year-over-year basis. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current year.

Wall Street Analyst Weigh In

VRTX has been the topic of several analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. HC Wainwright cut their price target on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a research report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, November 5th. Barclays cut their target price on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a report on Friday, December 20th. Finally, StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $494.04.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.